Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.34 |
| ▸ | DNM2 | P50570 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609268 | 0.78 | KCNH2 (0.53) | KCNH2SYKDNM2ESR1ESR2 | |
| SCHEMBL17561037 | 0.77 | DNM2 (0.55) | KCNH2DNM2ESR1ESR2 | |
| SCHEMBL1231970 | 0.77 | KMT2A (0.49) | KCNH2DNM2ESR1ESR2 | |
| SCHEMBL28547149 | 0.77 | KCNH2 (0.44) | KCNH2SPHK1 | |
| SCHEMBL22388247 | 0.76 | HRH4 (0.44) | SYKHTR7 | |
| SCHEMBL1028320 | 0.73 | KCNH3 (0.56) | KCNH2SYK | |
| SCHEMBL10580220 | 0.73 | KCNH2 (0.53) | KCNH2ESR1 | |
| Ammonia Solution, Strong SCHEMBL28095154 | 0.71 | KCNH2 (0.52) | KCNH2ESR1 | |
| SCHEMBL899234 | 0.71 | KCNH2 (0.55) | KCNH2LTB4R | |
| SCHEMBL11561943 | 0.71 | KCNH2 (0.55) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906914-B2 | Ethylene diamine modulators of fatty acid hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-09 | — | — | US | disclosed |
| US-8598202-B2 | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-03 | — | — | US | disclosed |
| US-8598202-B2 | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-03 | — | — | US | disclosed |
| EP-2254415-B1 | ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | US | disclosed |
| WO-2011022348-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2254415-A1 | ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2010-12-01 | — | — | EP | disclosed |
| EP-2254415-A1 | ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2010-12-01 | — | — | EP | disclosed |
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009105220-A1 | ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105220-A1 | ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | FAAH, FAAH2, APEH | KCNH2 2756/4885SYK 4319/4885LTB4R 372/4885 |
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | FAAH, FAAH2, HRH2 | KCNH2 2588/4885SYK 3542/4885LTB4R 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.